Indian Journal of Ophthalmology最新文献_第10页

Comment on "Brolucizumab-associated intraocular inflammation in Indian patients by VRSI study group". 对“VRSI研究组印度患者的brolucizumab相关眼内炎症”的评论。

IF 2.1 4区医学

Indian Journal of Ophthalmology Pub Date : 2025-06-01 Epub Date: 2025-05-28 DOI: 10.4103/IJO.IJO_2590_24

Sabyasachi Sengupta, Aditya Kelkar, Harsh H Jain

引用次数: 0

Evaluation of anterior scleral thickness in eyes with central serous chorioretinopathy. 中枢性浆液性脉络膜视网膜病变眼前巩膜厚度的评价。

IF 2.1 4区医学

Indian Journal of Ophthalmology Pub Date : 2025-06-01 Epub Date: 2025-05-28 DOI: 10.4103/IJO.IJO_3116_24

Parvathy Prabhakaran, B C Pradeep, Akanksha D Pandit, Pradeep Sagar, A Varsha, Shubhra Sweta, Suchitra Biswal, H N Ravishankar

{"title":"Evaluation of anterior scleral thickness in eyes with central serous chorioretinopathy.","authors":"Parvathy Prabhakaran, B C Pradeep, Akanksha D Pandit, Pradeep Sagar, A Varsha, Shubhra Sweta, Suchitra Biswal, H N Ravishankar","doi":"10.4103/IJO.IJO_3116_24","DOIUrl":"10.4103/IJO.IJO_3116_24","url":null,"abstract":"Purpose: To compare the anterior scleral thickness in eyes with central serous chorioretinopathy (CSC) and healthy eyes.Design: Cross-sectional observational study.Methods: The study included patients with CSC and age and gender-matched healthy individuals. The subfoveal choroidal thickness (SFCT) and scleral thickness at 3 mm, 4 mm, and 8 mm posterior to the scleral spur were measured using swept source optical coherence tomography (Topcon DRI-OCT Triton plus).Results: The study included 35 eyes with CSC and 35 control eyes. In CSC group, 82.86% were simple and 17.14% were complex. There was no statistically significant difference in the scleral thickness in CSC and control groups. Though the sclera was thicker in the complex CSC group compared to simple CSC at 3 mm (nasal: 724.33 ± 180.53 vs 658.48 ± 57.63, temporal: 696.17 ± 212.91 vs 628.83 ± 107.7) and 4 mm (nasal: 656.67 ± 109.34 vs 621.62 ± 79.31, temporal: 640.17 ± 191.31 vs 616.48 ± 86.30), the difference was not statistically significant. A moderate negative correlation was noted between SFCT and scleral thickness at 8 mm (r -0.349) and 3 mm on the nasal side (r -0.388) in the control group. A moderate negative correlation was noted between SFCT and scleral thickness at 4 mm (r -0.377) and 3 mm (r -0.403) on the temporal side in CSC group.Conclusion: The anterior scleral thickness was similar in CSC and healthy eyes. As the study sample predominantly included simple CSC, the findings indicate that the anterior scleral thickness may not be involved in the pathogenesis of simple CSC.","PeriodicalId":13329,"journal":{"name":"Indian Journal of Ophthalmology","volume":"73 6","pages":"833-836"},"PeriodicalIF":2.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12178366/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144158290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

OCT angiography in polycythemia vera. 真性红细胞增多症的OCT血管造影。

IF 2.1 4区医学

Indian Journal of Ophthalmology Pub Date : 2025-06-01 Epub Date: 2025-05-28 DOI: 10.4103/IJO.IJO_2562_24

Pradeep K Panigrahi

引用次数: 0

Visual loss and blurred optic discs. 视力丧失和视盘模糊。

IF 2.1 4区医学

Indian Journal of Ophthalmology Pub Date : 2025-06-01 Epub Date: 2025-05-30 DOI: 10.4103/IJO.IJO_2526_24

Ana Bárbara Dias Lopes Urzedo, Bruna Predabon, Kenzo Hokazono

引用次数: 0

Comments on: Clinicopathologic study of caruncular lesions. 点评：环形病变的临床病理研究。

IF 2.1 4区医学

Indian Journal of Ophthalmology Pub Date : 2025-06-01 Epub Date: 2025-05-30 DOI: 10.4103/IJO.IJO_2419_24

Soham S Pal, Md Shahid Alam

引用次数: 0

Clinical profile and visual outcomes in ethambutol-induced toxic optic neuropathy. 乙胺丁醇引起的中毒性视神经病变的临床特点和视力结果。

IF 2.1 4区医学

Indian Journal of Ophthalmology Pub Date : 2025-06-01 Epub Date: 2025-05-30 DOI: 10.4103/IJO.IJO_1807_24

Jenil Sheth, Virender Sachdeva, Ashima Goyal, Aditi Parikh, Rohan Nalawade, Hardik Nanavati, Ramesh Kekunnaya

{"title":"Clinical profile and visual outcomes in ethambutol-induced toxic optic neuropathy.","authors":"Jenil Sheth, Virender Sachdeva, Ashima Goyal, Aditi Parikh, Rohan Nalawade, Hardik Nanavati, Ramesh Kekunnaya","doi":"10.4103/IJO.IJO_1807_24","DOIUrl":"10.4103/IJO.IJO_1807_24","url":null,"abstract":"Purpose: To characterize the severity of vision loss, dose-related adverse effects, and visual outcomes in ethambutol-induced toxic optic neuropathy (ETON) patients.Methods: A prospective observational study was conducted in a tertiary eye center in South India between July 2019 and December 2021. Consecutive adults (age >18 years) taking revised antitubercular regimens and diagnosed with ETON were included. Data collected regarding patient demographics, presentation, dose-related severity of vision loss, and visual outcomes after drug discontinuation were analyzed.Results: We analyzed 214 eyes from 107 patients (mean age: 51.1 ± 13 years; male: female ratio = 2:1). The median follow-up time was 11 months (interquartile range: 4-14 months). Mean visual acuity improved from 1.2 ± 0.6 log of minimum angle of resolution (logMAR) at presentation to 0.8 ± 0.6 logMAR at the final follow-up. Patients above 60 years old had the worst visual acuity at presentation and had the least improvement at the last follow-up compared to those in younger age groups (1.3-1.2 logMAR, P = 0.2). The mean exposure time to ethambutol was 6.8 ± 3.3 months, and the mean dose was 1042 ± 247 mg/day, that is, 16.7 ± 4 mg/kg/day. Mean presenting best corrected visual acuity (BCVA; 1.3 ± 0.6 logMAR) was worse in patients taking a higher dose of ethambutol (≥16 mg/kg) compared to those taking <16 mg/kg (mean BCVA: 1 ± 0.5 logMAR).Conclusion: Higher age and higher doses of ethambutol were associated with an increased risk of vision loss and worse vision at presentation. Prolonged exposure to high-dose ethambutol, as in fixed drug dose combinations, leads to severe visual impairment which might be partially reversible.","PeriodicalId":13329,"journal":{"name":"Indian Journal of Ophthalmology","volume":"73 Suppl 3","pages":"S484-S491"},"PeriodicalIF":2.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12178413/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144181489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comments on: A study on the association of A-scan parameters and intraoperative complications during cataract surgery in eyes with pseudoexfoliation syndrome. 评论：假性角膜脱落综合征白内障手术中A扫描参数与术中并发症的关系研究。

IF 2.1 4区医学

Indian Journal of Ophthalmology Pub Date : 2025-06-01 Epub Date: 2025-05-30 DOI: 10.4103/IJO.IJO_554_25

Mithun Thulasidas

引用次数: 0

Artificial intelligence-powered smart vision glasses for the visually impaired. 为视障人士设计的人工智能智能眼镜。

IF 2.1 4区医学

Indian Journal of Ophthalmology Pub Date : 2025-06-01 Epub Date: 2025-05-30 DOI: 10.4103/IJO.IJO_1621_24

Devi Udayakumar, Sarika Gopalakrishnan, Aparna Raghuram, Arathy Kartha, Arun Kumar Krishnan, Ramkumar Ramamirtham, Ramu Muthangi, Ramakrishna Raju

{"title":"Artificial intelligence-powered smart vision glasses for the visually impaired.","authors":"Devi Udayakumar, Sarika Gopalakrishnan, Aparna Raghuram, Arathy Kartha, Arun Kumar Krishnan, Ramkumar Ramamirtham, Ramu Muthangi, Ramakrishna Raju","doi":"10.4103/IJO.IJO_1621_24","DOIUrl":"10.4103/IJO.IJO_1621_24","url":null,"abstract":"Purpose: In India, 4.80 million people are blind, and 4.69 million have severe visual impairment. Globally, the digital era and the advent of artificial intelligence devices offer solutions for daily challenges faced by the visually impaired, but they are often expensive. This study evaluates the acceptance and usability of a cost-effective AI-powered spectacle-mounted assistive device in a multicentric Indian cohort.Methods: Smart vision glass (SVG) is a lightweight tool, mounted on a spectacle frame with braille-coded keys and a real-time voice interface for guiding the visually impaired, and is connected to a smartphone Android App. The four major functions of the device are as follows: \"Things Around You,\" \"Reading,\" \"Walking Assistance,\" and \"Face Recognition.\" Ninety participants were recruited from five vision rehabilitation centers across India, and feedback was collected after a month's usage.Results: The mean age of the participants was 23.5 years (range: 6 to 56 years) with 58.9% male; 51% from rural areas; and 64.4% students. As per the World Health Organization (WHO) classification, 90% of the participants were blind (best corrected visual acuity in better eye less than 3/60). A total of 100% of the participants were able to access all the functions of the SVG. Participants reported a positive experience with \"Reading\" (72.9%), \"Things Around You\" (44.7%), \"Face Recognition\" (36.5%), and \"Walking Assistance\" (22.4%). About 2/3rd of the participants utilized the device for an hour or more per day.Conclusion: SVG is a promising cost-effective device for the blind and severe visually impaired in aiding their day-to-day challenges and becoming self-reliant.","PeriodicalId":13329,"journal":{"name":"Indian Journal of Ophthalmology","volume":"73 Suppl 3","pages":"S492-S497"},"PeriodicalIF":2.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12178407/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144181993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of topical nepafenac 0.1% and 0.3% on aqueous flare and macular thickness in patients with pseudoexfoliation following cataract surgery. 0.1%和0.3%外用尼泊芬酸对白内障手术后假性角膜脱落患者水光斑和黄斑厚度的影响。

IF 2.1 4区医学

Indian Journal of Ophthalmology Pub Date : 2025-06-01 Epub Date: 2025-04-17 DOI: 10.4103/IJO.IJO_2916_24

Yusuf B Akbas, Fahri O Aydin, Merve Kelebek, Semih Cakmak, Ali Ceylan, Zeynep Serikoglu Akbas, Yusuf Yildirim, Burcin Kepez Yildiz

{"title":"Comparison of topical nepafenac 0.1% and 0.3% on aqueous flare and macular thickness in patients with pseudoexfoliation following cataract surgery.","authors":"Yusuf B Akbas, Fahri O Aydin, Merve Kelebek, Semih Cakmak, Ali Ceylan, Zeynep Serikoglu Akbas, Yusuf Yildirim, Burcin Kepez Yildiz","doi":"10.4103/IJO.IJO_2916_24","DOIUrl":"10.4103/IJO.IJO_2916_24","url":null,"abstract":"Purpose: To evaluate and compare the efficacy of topical nepafenac 0.1% administered three times daily versus nepafenac 0.3% administered once daily in patients with pseudoexfoliation syndrome (PEX) following routine cataract surgery.Methods: In this retrospective cohort study, patients with PEX undergoing routine cataract surgery were divided into two groups for analysis. Group 1 received nepafenac 0.1% three times daily, while Group 2 received nepafenac 0.3% once daily. In both groups, nepafenac was started 1 day before surgery and continued for 2 weeks postoperatively. Anterior chamber flare was quantified using laser flare photometry (LFP), and central macular thickness (CMT) was measured using optical coherence tomography. Measurements were taken preoperatively, at 1 week, and at 6 weeks postoperatively.Results: The study included 85 eyes from 85 patients, with 39 eyes in Group 1 and 46 eyes in Group 2. During the first postoperative week, Group 2 showed a significant reduction in LFP measurements ( P = 0.047) compared to Group 1. Notably, no significant difference was observed between the groups at the preoperative visit or at postoperative week 6. Comparisons of preoperative, 1-week, and 6-week postoperative CMT values also revealed no significant differences between the groups.Conclusion: Nepafenac 0.3% used in routine cataract surgery in patients with PEX was shown to be at least as effective as nepafenac 0.1% in terms of aqueous flare and CMT. Aqueous flare values were more favorable with nepafenac 0.3% during the first week. In addition, the convenience of once-daily dosing may offer further advantages.","PeriodicalId":13329,"journal":{"name":"Indian Journal of Ophthalmology","volume":" ","pages":"S424-S427"},"PeriodicalIF":2.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12178409/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143997924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The clinical spectrum of bulbar conjunctival rhinosporidiosis. 球结膜鼻孢子虫病的临床特征。

IF 2.1 4区医学

Indian Journal of Ophthalmology Pub Date : 2025-06-01 Epub Date: 2025-04-17 DOI: 10.4103/IJO.IJO_52_24

Prasansha Narnoli, Suryasnata Rath, Samir Mohapatra, Mukesh Jain, Devjyoti Tripathy

{"title":"The clinical spectrum of bulbar conjunctival rhinosporidiosis.","authors":"Prasansha Narnoli, Suryasnata Rath, Samir Mohapatra, Mukesh Jain, Devjyoti Tripathy","doi":"10.4103/IJO.IJO_52_24","DOIUrl":"10.4103/IJO.IJO_52_24","url":null,"abstract":"Purpose: To report the clinical spectrum of bulbar conjunctival rhinosporidiosis at a tertiary eye care oculoplastics facility.Methods: Retrospective chart review of biopsy-proven ocular and adnexal rhinosporidiosis over a five-year period (2017-2022). Demographic details, clinical presentation, management interventions, and outcomes in a series of cases with bulbar conjunctival rhinosporidiosis were documented and analyzed.Results: A total of 14 cases of biopsy-proven bulbar conjunctival rhinosporidiosis were included in this study. These formed 22.2% of all cases of ocular adnexal rhinosporidiosis and 46.7% of all conjunctival cases diagnosed within the study period. All the cases underwent surgical excision of the conjunctival mass with five (35.7%) requiring a scleral patch graft for scleral thinning with or without staphyloma formation. Most patients had a good outcome on medium to long-term follow-up.Conclusions: Even though tarsal conjunctival involvement is reported as the most common form of conjunctival rhinosporidiosis in the literature, in our series, bulbar conjunctival disease comprised nearly half of all conjunctival cases, and over 20% of all adnexal cases. Most appear to do well with complete surgical excision of the granuloma. Rarely, long-standing cases may develop scleral thinning with or without staphyloma formation which may need major tectonic support to protect the integrity of the eyeball. Most of these also appear to do well on medium to long-term follow-up.","PeriodicalId":13329,"journal":{"name":"Indian Journal of Ophthalmology","volume":" ","pages":"S389-S393"},"PeriodicalIF":2.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12178411/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143984645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0